| Title: |
The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis. |
| Authors: |
Ashrafi, Sadra, Hatami, Hossein, Bidhendi-Yarandi, Razieh, Panahi, Mohammad Hossein |
| Source: |
BMC Endocrine Disorders; 1/2/2024, Vol. 24 Issue 1, p1-10, 10p |
| Subject Terms: |
ONLINE information services, THYROID diseases, COVID-19, META-analysis, CONFIDENCE intervals, SYSTEMATIC reviews, HYPERTHYROIDISM, ACQUISITION of data, MEDICAL records, ISOLATION (Hospital care), MEDLINE, GREY literature |
| Geographic Terms: |
INDIA |
| Abstract: |
Objectives: To conduct a systematic review and meta-analysis to evaluate the prevalence of thyroid disorders in COVID-19 patients. Data sources: Scopus, PubMed, ISI Web of Science, and Google Scholar databases were used in this review. We also consider the results of grey literature. Study selections: Cohort, cross-sectional, and case-control studies were included. Data extraction and synthesis: The required data were extracted by the first author of the article and reviewed by the second author. The Pooled prevalence of outcomes of interest was applied using the meta-prop method with a pooled estimate after Freeman-Tukey Double Arcsine Transformation to stabilize the variances. Outcomes and measured: The different thyroid disorders were the main outcomes of this study. The diseases include non-thyroidal illness syndrome, thyrotoxicosis, hypothyroidism, isolated elevated free T4, and isolated low free T4. Results: Eight articles were included in our meta-analysis(Total participants: 1654). The pooled prevalence of events hypothyroidism, isolated elevated FT4, isolated low FT4, NTIS, and thyrotoxicosis were estimated (Pooled P = 3%, 95% CI:2–5%, I2: 78%), (Pooled P = 2%, 95% CI: 0–4%, I2: 66%), (Pooled P = 1%, 95% CI: 0–1%, I2: 0%), (Pooled P = 26%, 95% CI: 10–42%, I2: 98%), and (Pooled P = 10%, 95% CI: 4–16%, I2: 89%), respectively. Conclusion: Thyroid dysfunction is common in COVID-19 patients, with a high prevalence of non-thyroidal illness syndrome (NTIS) and thyrotoxicosis. Our meta-analysis found a 26% prevalence of NTIS and a 10% prevalence of thyrotoxicosis. Systematic review registration: PROSPERO CRD42022312601. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Endocrine Disorders is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
